CoChat
Sign Up
Cited by 479

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease

Ferrer, Isidre, Rovira, Mercé Boada, Guerra, María Luisa Sánchez, Rey, María Jesús, Costa‐Jussá, Frederic·2004·Brain Pathology
DOI 10.1111/j.1750-3639.2004.tb00493.x
Open this paper in CoChat — free account

Abstract

Immunizing transgenic PDAPP mice, which overexpress mutant APP and develop β‐amyloid deposition resembling plaques in Alzheimer's disease (AD), results in a decrease of amyloid burden when compared with non treated transgenic animals im‐munization with amyloid β peptide has been initiated in a randomised pilot study in AD. Yet a minority of patients developed a neurological complication consistent with meningoencephalitis and one patient died; the trial has been stopped. Neuropathological examination in that patient showed meningoencephalitis and focal atypically low numbers of diffuse and neuritic plaques but not of vascular amyloid nor regression of tau pathology in neurofibrillary tangles and neuropil threads. The present neuropathological study reports the second case of menigoencephalitis following immunization with amyloid‐β peptide in AD, and has been directed toward exploring mechanisms underlying decreased tau pathology in relation‐ with amyliod deposit regression, and possible molecular bases involved in the inflammatory response following immunization. Inflammatory infiltrates were composed of CD8+, CD3+, CD5+ and, rarely, CD7+ lymphocytes, whereas B lymphocytes and T cytotoxic cells CD16, CD57, TIA and graenzyme were negative. Characteristic neuropathological findings were focal depletion of diffuse and neuritic plaques, but not of amyloid angiopathy, and the presence of small numbers of extremely dense(collapsed) plaques surrounded by active microglia, and multinucleated giant cells filled with dense Aβ 42 and Aβ 40, in addition to severe small cerebral blood Reduced amyloid burden was accompanied by low amyloid‐associated oxidative stress responses (reduced superoxide dismutase‐1:SOD‐1 expression) and by local inhibition of the stress‐activated protein kinase/c‐Jun N‐terminal kinase (SAPK/JNK) and p38 kinase which are involved in tau phosphorylation. These results support the amyloid cascade of tau phosphorylation in AD regarding phosphorylation of tau in neurofibrillary tangles and β‐amyloid deposition in neuritic plaques, but not of tau in neurofibrillary tangles and threads. Furthermore, amyloid reduction was accompanied by increased expression of the PA28α/β inductor, and of LMP7, LMP2 and MECL1 subunits of the immunopro‐teasome in microglial and inflammatory cells surrounding collapsed plaques, and in multinucleated giant cells.Immunoproteasome subunit expression was accompanied by local presentation of MHC class molecules. Release of antigenic peptides derived from β‐amyloid processing may enhance T‐cell inflammatory responses accounting for the meningoencephalitis following amyloid‐β peptide immunization

Overview

Integrity signals

Registry

Crossref · 10.1111/j.1750-3639.2004.tb00493.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 44

  1. 10.1093/jnen/60.12.1190 · DOI
  2. 10.1016/S0301-0082(98)00055-0 · DOI
  3. 10.1159/000067423 · DOI
  4. 10.1038/nm0302-199b · DOI
  5. 10.1146/annurev.biophys.28.1.295 · DOI
  6. 10.1007/978-1-4615-4885-0_14 · DOI
  7. 10.1016/0304-3940(90)90754-W · DOI
  8. 10.1038/415462a · DOI
  9. 10.1093/emboj/17.24.7151 · DOI
  10. 10.1038/35096075 · DOI
  11. Duyckaerts C, 2003, Neurodegeneration: The molecular pathology of dementia and movement disorders, 47
  12. Ferrer I, 2002, Glychogen synthase kinase‐3 (GSK‐3) is associated with neuronal and glial hyper‐phosphorylated tau deposits in Alzheimer's disease, pick's disease, progressive supranuclear palsy and corticobasal degeneration, Acta Neuropathol, 104, 583, 10.1007/s00401-002-0587-8 · DOI
  13. 10.1007/s007020100016 · DOI
  14. Ferrer I, 2001, Prion protein expre‐sion in senile plaques in Alzheimer's disease, Acta Neuropathol, 101, 49, 10.1007/s004010000271 · DOI
  15. 10.1097/00005072-199803000-00002 · DOI
  16. Furuta A, 1995, Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus, Am J Pathol, 146, 357
  17. 10.1146/annurev.biochem.67.1.425 · DOI · Paper page
  18. 10.1002/ana.410350514 · DOI
  19. 10.1038/35050110 · DOI · Paper page
  20. Jellinger KA, 2003, Incidence of cerebrovascular lesions in Alzheimer's disease: a post‐mortem study, Acta Neuropathol, 105, 14, 10.1007/s00401-002-0634-5 · DOI
  21. 10.1046/j.1471-4159.2003.01642.x · DOI · Paper page
  22. 10.1111/j.1749-6632.1993.tb23028.x · DOI
  23. 10.1046/j.1365-2990.2001.00335.x · DOI
  24. 10.1126/science.1058189 · DOI · Paper page
  25. 10.1016/S0300-9084(01)01236-6 · DOI
  26. 10.1111/j.1750-3639.1999.tb00215.x · DOI
  27. 10.1007/978-3-7091-6467-9_13 · DOI
  28. 10.1093/jnen/60.4.357 · DOI
  29. 10.1038/35050116 · DOI
  30. Pappolla MA, 1992, Immunohistochemical evidence of oxidative stress in Alzheimer's disease, Am J Pathol, 140, 621
  31. Pei JJ, 1999, Distribution of glycogen synthase kinase 3 beta (GSK‐3β) for Alzheimer disease neurofibrillary tangle, J Neu-ropathol Exp Neurol, 58, 1010, 10.1097/00005072-199909000-00011 · DOI · Paper page
  32. 10.3233/JAD-1998-1103 · DOI
  33. 10.1126/science.1078259 · DOI · Paper page
  34. Plemper RK, 2002, Progress in molecular and sub‐cellular biology, 61
  35. 10.1146/annurev.immunol.17.1.739 · DOI
  36. 10.3233/JAD-2002-4509 · DOI
  37. 10.1002/1521-4141(200012)30:12<3672::AID-IMMU3672>3.0.CO;2-B · DOI
  38. 10.1016/S0002-9440(10)61715-4 · DOI
  39. 10.1046/j.1471-4159.1998.70052212.x · DOI
  40. 10.1016/S0065-2776(08)60885-8 · DOI
  41. 10.1002/1531-8249(200010)48:4<567::AID-ANA3>3.0.CO;2-W · DOI
  42. 10.1159/000067426 · DOI
  43. 10.1046/j.1471-4159.2001.00046.x · DOI
  44. 10.1093/jnen/59.10.880 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Ferrer, I., Rovira, M. B., Guerra, M. L. S., Rey, M. J., & Costa‐Jussá, F.
Venue
Brain Pathology
Publisher
Wiley
Published
2004-01
Volume
14
Issue
1
Pages
11-20
ISSN
  • 1015-6305
  • 1750-3639
DOI
10.1111/j.1750-3639.2004.tb00493.x
Cited by
479
References
7
Language
en
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 825 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review